Impaired central set point of thyroid homeostasis during quetiapine treatment in the acute phase of schizophrenia

• Published in: Schizophrenia research 2022-03, Vol.241, p.244-250
• Main Authors: Zhao, Ying, Guan, Qiongge, Shi, Jingyi, Sun, Jiewei, Wang, Qi, Yang, Jianzhou, Retnakaran, Ravi, Han, Jinhong, Zhang, Xiangyang, Hao, Wei, Huang, Xin, Zhang, Ruiling, Zhai, Desheng, Wen, Shi Wu
• Format: Article
• Language: English
• Subjects: Central set point; Quetiapine; Schizophrenia; Thyroid homeostasis
• ISSN: 0920-9964; 1573-2509
• DOI: 10.1016/j.schres.2022.02.010

To evaluate the impact of quetiapine treatment on central set point of thyroid homeostasis in patients with acute phase schizophrenia. During Jan. 2016 to Dec. 2018, we conducted a retrospective cohort study in “the Second Affiliated Hospital of Xinxiang Medical University”. All patients admitted for treatment of schizophrenia being euthyroid at admission and reevaluated for thyroid function during hospitalization were recruited and followed until discharge. Patients treated with mood stabilizers during hospitalization were excluded. Quetiapine use was the exposure measure. The primary outcomes were the parameters of central set point of thyroid homeostasis measured by “thyroid-stimulating hormone (TSH) index” and “thyroid feedback quantile-based index (TFQI)”. Multiple regression models were used to estimate the association between quetiapine exposure and outcomes. A total of 1302 patients were enrolled in this study. Quetiapine exposure was associated with a more significant decline in the TSH index and TFQI, and the adjusted β and 95% confidence interval (CI) were −0.12 (−0.22, −0.01) and −0.10 (−0.15, −0.05), respectively. A dose-response association between quetiapine exposure and decline in TSH index and TFQI was observed (P